Roivant Sciences to Take Public via Montes Archimedes Acquisition Corp (MAAC) Business Combination

Roche Buys Telavant Holdings (Roivant/Pfizer) for $7.1B+

October 26, 2023

Healthcare Services

Roche entered into a definitive agreement to acquire Telavant Holdings, a company jointly owned by Roivant and Pfizer, for an upfront purchase price of $7.1 billion plus a near-term $150 million milestone payment. The deal gives Roche full rights to further develop, manufacture, and commercialize Telavant’s TL1A-directed antibody RVT-3101 in the US and Japan, with Pfizer retaining commercialization rights outside those territories.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

Avant Technologies Proposes Acquisition of Ainnova Tech to Consolidate Vision AI JV

May 13, 2025

Healthcare Services

Avant Technologies has entered formal negotiations to acquire its joint-venture partner Ainnova Tech (operating through Ai-nova Acquisition Corp.), aiming to merge the businesses ahead of an FDA pre-submission meeting. The deal is intended to streamline regulatory coordination, speed clinical development and support U.S. market entry for the Vision AI clinical screening platform currently piloted across Latin America.

Merck to Acquire Acceleron Pharma Inc for $11.5B

September 30, 2021

Biotechnology

Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.

ArchiMed Acquires ImaBiotech and Pyxant Labs; Pyxant Acquires LabCorp/Covance Salt Lake City Site

July 6, 2021

Healthcare Services

European healthcare-focused private equity firm ArchiMed completed three simultaneous transactions to create a market leader in bioanalytical services: it acquired French molecular-imaging and bioanalysis specialist ImaBiotech and Colorado Springs-based Pyxant Labs, while Pyxant also acquired LabCorp/Covance's Salt Lake City bioanalytical and oligonucleotide studies site. The combined moves expand ArchiMed's capabilities and North American footprint in bioanalytical testing for clinical trials.

Voyager Acquisition Corp and VERAXA Biotech Announce Form F-4 Filing for Proposed Business Combination

July 17, 2025

Healthcare Services

VERAXA Biotech AG and Voyager Acquisition Corp. (a SPAC) have filed a Form F-4 registration statement with the SEC in connection with their proposed business combination announced in April 2025. Under the terms, VERAXA shareholders are expected to roll over 100% of their equity and receive approximately 130 million ordinary shares of the combined company, with the deal expected to close in Q4 2025.